Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

BeiGene Says BTK Inhibitor Bests Competitor in Phase III Leukemia Trial

publication date: Apr 11, 2022

Beijing’s BeiGene announced its BTK inhibitor showed a better overall response rate than ibrutinib in a Phase III trial for leukemia. BeiGene said Brukinsa produced an ORR of 80.4% versus 72.9% for ibrutinib. The ALPINE trail enrolled 652 patients who were followed for a median 24.2 months in a multination trial. The next read of ALPINE data will be the final analysis for progression free survival. Brukinsa is already approved for three indications in the US: mantle cell lymphoma, Waldenström’s macroglobulinemia and marginal zone lymphoma. More details....

Stock Symbol: (NSDQ: BGNE; HK: 06160; SHA: 688235)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Singapore and Digital
April 26-27, 2023
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China